Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology patent. This marks the company's first Chinese patent and will provide protection into the 2040s.
The patent, exclusively licensed from Cleveland Clinic, covers composition of matter protection for Anixa's novel breast cancer treatment and prevention approach. The vaccine targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers.
This expansion is particularly significant as breast cancer has become the most commonly diagnosed cancer among women in China, with hundreds of thousands of new cases annually. The patent complements existing protection in the United States and other key global markets.
Anixa Biosciences (NASDAQ: ANIX) ha ricevuto una Notifica di Concessione dall'Amministrazione Nazionale della Proprietà Intellettuale cinese per il brevetto relativo alla sua tecnologia per il vaccino contro il cancro al seno. Si tratta del primo brevetto in Cina dell'azienda e garantirà protezione fino agli anni '40 del 2040.
Il brevetto, concesso in licenza esclusiva dalla Cleveland Clinic, offre protezione sulla composizione per il nuovo approccio di Anixa al trattamento e alla prevenzione del cancro al seno. Il vaccino è diretto contro l'alfa-lattalbumina umana, una proteina legata alla lattazione che viene espressa in modo anomalo in alcuni tumori mammari.
Questa estensione è particolarmente rilevante poiché il cancro al seno è diventato il tumore più frequentemente diagnosticato tra le donne in Cina, con centinaia di migliaia di nuovi casi ogni anno. Il brevetto integra le protezioni già esistenti negli Stati Uniti e in altri mercati globali chiave.
Anixa Biosciences (NASDAQ: ANIX) ha recibido un Aviso de Concesión por parte de la Administración Nacional de Propiedad Intelectual de China para su patente de tecnología de vacuna contra el cáncer de mama. Este constituye el primer patente en China de la compañía y proporcionará protección hasta la década de 2040.
La patente, licenciada en exclusiva por la Cleveland Clinic, cubre la protección de la composición de la materia del novedoso enfoque de Anixa para el tratamiento y la prevención del cáncer de mama. La vacuna se dirige a la α‑lactalbumina humana, una proteína asociada a la lactación que se expresa de forma anómala en ciertos cánceres de mama.
Esta expansión es especialmente relevante dado que el cáncer de mama se ha convertido en el cáncer más diagnosticado entre las mujeres en China, con cientos de miles de casos nuevos anuales. La patente complementa la protección ya existente en Estados Unidos y en otros mercados globales clave.
Anixa Biosciences (NASDAQ: ANIX)는 중국 국가지식재산국으로부터 유방암 백신 기술에 대한 특허 허가 통지(Notice of Allowance)를 받았습니다. 이번 허가는 회사의 첫 중국 특허로, 2040년대까지 보호를 제공합니다.
이 특허는 Cleveland Clinic으로부터 독점 라이선스를 받은 것으로, Anixa의 새로운 유방암 치료·예방 접근법에 대한 물질조성(composition of matter) 보호를 포함합니다. 이 백신은 수유와 관련된 단백질인 인간 α‑락토알부민을 표적으로 하며, 특정 유방암에서 비정상적으로 발현됩니다.
유방암은 중국에서 여성들 사이에 가장 흔히 진단되는 암이 되어 연간 수십만 건의 신규 환자가 발생하고 있어 이번 확장은 특히 중요합니다. 해당 특허는 미국과 기타 주요 글로벌 시장에서의 기존 보호와도 보완 관계에 있습니다.
Anixa Biosciences (NASDAQ: ANIX) a reçu un Avis d'acceptation de la part de l'Administration nationale de la propriété intellectuelle chinoise pour son brevet portant sur la technologie de vaccin contre le cancer du sein. Il s'agit du premier brevet en Chine de la société et il offrira une protection jusqu'aux années 2040.
Le brevet, concédé sous licence exclusive par la Cleveland Clinic, couvre la protection de la composition de la matière pour la nouvelle approche d'Anixa en matière de traitement et de prévention du cancer du sein. Le vaccin cible l'α‑lactalbumine humaine, une protéine liée à la lactation qui est exprimée de manière anormale dans certains cancers du sein.
Cette extension est particulièrement importante car le cancer du sein est devenu le cancer le plus fréquemment diagnostiqué chez les femmes en Chine, avec des centaines de milliers de nouveaux cas chaque année. Le brevet complète la protection existante aux États‑Unis et sur d'autres marchés mondiaux clés.
Anixa Biosciences (NASDAQ: ANIX) hat von der chinesischen Nationalen Verwaltung für geistiges Eigentum eine Notice of Allowance für ihr Patent zur Brustkrebs-Vakzin-Technologie erhalten. Dies ist das erste chinesische Patent des Unternehmens und sichert Schutz bis in die 2040er Jahre.
Das Patent, das exklusiv von der Cleveland Clinic lizenziert ist, umfasst einen Composition-of-Matter-Schutz für Anixas neuartigen Ansatz zur Behandlung und Prävention von Brustkrebs. Der Impfstoff richtet sich gegen das menschliche α‑Laktalbumin, ein mit dem Stillen assoziiertes Protein, das in bestimmten Brustkrebserkrankungen fehlreguliert exprimiert wird.
Diese Erweiterung ist besonders bedeutsam, da Brustkrebs in China die am häufigsten diagnostizierte Krebserkrankung bei Frauen geworden ist, mit Hunderttausenden neuer Fälle pro Jahr. Das Patent ergänzt den bereits bestehenden Schutz in den USA und anderen wichtigen globalen Märkten.
- Secured first Chinese patent protection for breast cancer vaccine technology extending into 2040s
- Expands intellectual property coverage in one of world's largest and fastest-growing patient markets
- Strategic positioning in China where breast cancer is the most commonly diagnosed cancer among women
- Complements existing patents in US and other key global markets
- None.
Insights
Anixa's new Chinese patent significantly expands global IP protection for its breast cancer vaccine, strengthening long-term commercial potential in a massive market.
This Chinese patent allowance represents a strategic expansion of Anixa's intellectual property portfolio into one of the world's largest healthcare markets. Securing composition of matter protection—the strongest form of pharmaceutical patent—provides Anixa exclusive rights to their breast cancer vaccine technology in China until at least the 2040s. This 20+ year exclusivity window is particularly valuable for a preventative cancer vaccine, as it allows sufficient time for clinical development, regulatory approval, and commercial exploitation.
The timing is especially significant considering China's rapidly growing breast cancer burden. Unlike the patent portfolios of many biotechs that focus primarily on Western markets, Anixa is building comprehensive global coverage aligned with disease epidemiology. This patent complements existing protection in the US and other jurisdictions, creating a more licensable and commercially valuable global IP estate.
The underlying technology—targeting α-lactalbumin, a protein normally only expressed during lactation but aberrantly expressed in certain breast cancers—employs a clever "retired protein" strategy. This approach potentially enables selective immune targeting while minimizing off-target effects, addressing a fundamental challenge in cancer vaccine development.
For investors, this patent allowance indicates reduced competition risk in a key market and enhanced partnership potential with Chinese pharmaceutical companies, who strongly prefer technologies with local patent protection. While still in clinical development, this strategic IP expansion positions Anixa to capture value from China's growing focus on innovative preventative oncology technologies.
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine
Expands global intellectual property coverage in markets with high breast cancer incidence
New patent will provide IP protection of Breast Cancer Vaccine in
With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Chinese patent complements patents issued in
"This newly allowed patent further illustrates the continued recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the
Breast cancer has become the most commonly diagnosed cancer among women in
Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue.
By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-chinese-national-intellectual-property-administration-for-patent-covering-breast-cancer-vaccine-technology-302533982.html
SOURCE Anixa Biosciences, Inc.
FAQ
What patent did Anixa Biosciences (NASDAQ: ANIX) receive in China?
How does Anixa's breast cancer vaccine technology work?
Why is the Chinese patent important for Anixa Biosciences?
Who developed the breast cancer vaccine technology licensed to Anixa?
What is the current development status of Anixa's breast cancer vaccine?
